Lifastuzumab vedotin (INN; development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.

This drug was developed by Genentech/Roche.

References